Skip to main content

Table 1 Baseline demographic and clinical characteristics in the 2 groups

From: Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study

Variable

Group A

Pioglitazone

(n = 42)

Group B

Other treatment

(n = 39)

P

value

Age, years (range)

64.3 ± 8.1 (44-77)

64.8 ± 7.5 (48-81)

0.78

Female gender, n (%)

27 (64)

28 (72)

0.49

Hypertensives, n (%)

31 (74)

32 (82)

0.27

Hyperlipidaemics, n (%)

26 (62)

27 (69)

0.64

Ever smokers, n (%)

14 (33)

10 (26)

0.48

Family history of CAD

23 (55)

24 (62)

0.35

Duration of diabetes, years

10.2 ± 6.6

9.0 ± 6.9

0.41

Metformin

31 (74)

26 (67)

0.63

Sulfonylurea

31 (74)

27 (69)

0.81

Metformin & Sulfonylurea

20 (48)

15 (38)

0.50

Antihypertensives, n (%)

27 (64)

27 (69)

0.81

Diuretics, n (%)

6 (14)

8 (21)

0.56

ACE or AT-II inhibitors, n (%)

22 (52)

22 (56)

0.82

β-blockers, n (%)

1 (2)

3 (8)

0.35

Calcium channel blockers, n (%)

12 (29)

11 (28)

1.00

Statin, n (%)

18 (43)

17 (44)

1.00

Antiplatelets, n (%)

5 (12)

4 (10)

1.00

  1. Mean ± SD unless otherwise stated.
  2. CAD, coronary artery disease; ACE, angiotensin converting enzyme; AT-II, angiotensin II.